Transfection with a cripto anti-sense plasmid suppresses endogenous cripto expression and inhibits transformation in a human embryonal carcinoma cell line

Gustavo Baldassarre, Caterina Bianco, Giampaolo Tortora, Angela Ruggiero, Mark Moasser, Ethan Dmitrovsky, A. Raffaele Bianco, Fortunato Ciardiello

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

CRIPTO is a member of the epidermal growth factor (FGF) gene family originally isolated from undifferentiated human NTERA2 clone D1 (NTZD1) multipotent embryonal carcinoma cells. Retinoic acid (RA) treatment of NT2D1 cells leads to a neuronal differentiation program and to concomitant loss of CRIPTO mRNA expression. To assess the role of CRIPTO in the control of NTZD1 cell growth or differentiation, these cells were treated with 3 anti-sense oligodeoxynucleotides complementary to the 5' end of the human CRIPTO mRNA. A dosedependent inhibition of monolayer and soft agar growth was observed with each of these CRIPTO anti-sense oligodeoxynucleotides but not with a control oligodeoxynucleotide of random sequence or with the 3 corresponding CRIPTO sense oligodeoxynucleotides. In addition, NTZD1 cells were transfected with a recombinant expression vector containing a 918-bp coding fragment of the human CRIPTO cDNA in the 3' to 5' orientation. NTZD1 CRIPT anti-sense transfectants exhibited a significantly reduced endogenous CRIPTO mRNA and protein, a 4- to 5-fold decrease in growth rate in monolayer and a 50-70% reduction in cloning efficiency in soft agar as compared with NT2D1 parental cells or with NT2D1 cells transfected with a plasmid containing the neomycin-resistance gene alone (NT2D1 neo cells). Finally, we examined the expression of immunophenotypic markers that are modulated during the differentiation of NT2D1 cells following RA treatment. The globoseries stage-specific embryonic antigen-3 recognized by the monoclonal antibody (MAb) SSEA-3 was expressed in 60% of undifferentiated parental NT2D1 or NT2D1 neo cells and in only 20% of NT2D1 CRIPTO anti-sense transfectants, whereas it was down-regulated in all cell lines following RA treatment. A neuroectodermal antigen recognized by the A2B5 MAb, which was not expressed in parental NT2D1, in NT2D1 neo or in CRIPTO anti-sense NT2D1 cells, was induced by RA treatment in all cell lines. Taken together, our results show that inhibition of endogenous CRIPTO expression in human embryonal carcinoma cells interferes with both transformation and differentiation.

Original languageEnglish
Pages (from-to)538-543
Number of pages6
JournalInternational Journal of Cancer
Volume66
Issue number4
DOIs
Publication statusPublished - May 16 1996

Fingerprint

Embryonal Carcinoma Stem Cells
Transfection
Plasmids
Cell Line
Oligodeoxyribonucleotides
Tretinoin
Messenger RNA
Agar
Cell Differentiation
Growth
Monoclonal Antibodies
Neomycin
Therapeutics
Epidermal Growth Factor
Genes
Organism Cloning
Complementary DNA
Clone Cells
Antigens

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Transfection with a cripto anti-sense plasmid suppresses endogenous cripto expression and inhibits transformation in a human embryonal carcinoma cell line. / Baldassarre, Gustavo; Bianco, Caterina; Tortora, Giampaolo; Ruggiero, Angela; Moasser, Mark; Dmitrovsky, Ethan; Bianco, A. Raffaele; Ciardiello, Fortunato.

In: International Journal of Cancer, Vol. 66, No. 4, 16.05.1996, p. 538-543.

Research output: Contribution to journalArticle

Baldassarre, Gustavo ; Bianco, Caterina ; Tortora, Giampaolo ; Ruggiero, Angela ; Moasser, Mark ; Dmitrovsky, Ethan ; Bianco, A. Raffaele ; Ciardiello, Fortunato. / Transfection with a cripto anti-sense plasmid suppresses endogenous cripto expression and inhibits transformation in a human embryonal carcinoma cell line. In: International Journal of Cancer. 1996 ; Vol. 66, No. 4. pp. 538-543.
@article{46c8d9d99d9944ff86c8ce3662c939dd,
title = "Transfection with a cripto anti-sense plasmid suppresses endogenous cripto expression and inhibits transformation in a human embryonal carcinoma cell line",
abstract = "CRIPTO is a member of the epidermal growth factor (FGF) gene family originally isolated from undifferentiated human NTERA2 clone D1 (NTZD1) multipotent embryonal carcinoma cells. Retinoic acid (RA) treatment of NT2D1 cells leads to a neuronal differentiation program and to concomitant loss of CRIPTO mRNA expression. To assess the role of CRIPTO in the control of NTZD1 cell growth or differentiation, these cells were treated with 3 anti-sense oligodeoxynucleotides complementary to the 5' end of the human CRIPTO mRNA. A dosedependent inhibition of monolayer and soft agar growth was observed with each of these CRIPTO anti-sense oligodeoxynucleotides but not with a control oligodeoxynucleotide of random sequence or with the 3 corresponding CRIPTO sense oligodeoxynucleotides. In addition, NTZD1 cells were transfected with a recombinant expression vector containing a 918-bp coding fragment of the human CRIPTO cDNA in the 3' to 5' orientation. NTZD1 CRIPT anti-sense transfectants exhibited a significantly reduced endogenous CRIPTO mRNA and protein, a 4- to 5-fold decrease in growth rate in monolayer and a 50-70{\%} reduction in cloning efficiency in soft agar as compared with NT2D1 parental cells or with NT2D1 cells transfected with a plasmid containing the neomycin-resistance gene alone (NT2D1 neo cells). Finally, we examined the expression of immunophenotypic markers that are modulated during the differentiation of NT2D1 cells following RA treatment. The globoseries stage-specific embryonic antigen-3 recognized by the monoclonal antibody (MAb) SSEA-3 was expressed in 60{\%} of undifferentiated parental NT2D1 or NT2D1 neo cells and in only 20{\%} of NT2D1 CRIPTO anti-sense transfectants, whereas it was down-regulated in all cell lines following RA treatment. A neuroectodermal antigen recognized by the A2B5 MAb, which was not expressed in parental NT2D1, in NT2D1 neo or in CRIPTO anti-sense NT2D1 cells, was induced by RA treatment in all cell lines. Taken together, our results show that inhibition of endogenous CRIPTO expression in human embryonal carcinoma cells interferes with both transformation and differentiation.",
author = "Gustavo Baldassarre and Caterina Bianco and Giampaolo Tortora and Angela Ruggiero and Mark Moasser and Ethan Dmitrovsky and Bianco, {A. Raffaele} and Fortunato Ciardiello",
year = "1996",
month = "5",
day = "16",
doi = "10.1002/(SICI)1097-0215(19960516)66:4<538::AID-IJC19>3.0.CO;2-3",
language = "English",
volume = "66",
pages = "538--543",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Transfection with a cripto anti-sense plasmid suppresses endogenous cripto expression and inhibits transformation in a human embryonal carcinoma cell line

AU - Baldassarre, Gustavo

AU - Bianco, Caterina

AU - Tortora, Giampaolo

AU - Ruggiero, Angela

AU - Moasser, Mark

AU - Dmitrovsky, Ethan

AU - Bianco, A. Raffaele

AU - Ciardiello, Fortunato

PY - 1996/5/16

Y1 - 1996/5/16

N2 - CRIPTO is a member of the epidermal growth factor (FGF) gene family originally isolated from undifferentiated human NTERA2 clone D1 (NTZD1) multipotent embryonal carcinoma cells. Retinoic acid (RA) treatment of NT2D1 cells leads to a neuronal differentiation program and to concomitant loss of CRIPTO mRNA expression. To assess the role of CRIPTO in the control of NTZD1 cell growth or differentiation, these cells were treated with 3 anti-sense oligodeoxynucleotides complementary to the 5' end of the human CRIPTO mRNA. A dosedependent inhibition of monolayer and soft agar growth was observed with each of these CRIPTO anti-sense oligodeoxynucleotides but not with a control oligodeoxynucleotide of random sequence or with the 3 corresponding CRIPTO sense oligodeoxynucleotides. In addition, NTZD1 cells were transfected with a recombinant expression vector containing a 918-bp coding fragment of the human CRIPTO cDNA in the 3' to 5' orientation. NTZD1 CRIPT anti-sense transfectants exhibited a significantly reduced endogenous CRIPTO mRNA and protein, a 4- to 5-fold decrease in growth rate in monolayer and a 50-70% reduction in cloning efficiency in soft agar as compared with NT2D1 parental cells or with NT2D1 cells transfected with a plasmid containing the neomycin-resistance gene alone (NT2D1 neo cells). Finally, we examined the expression of immunophenotypic markers that are modulated during the differentiation of NT2D1 cells following RA treatment. The globoseries stage-specific embryonic antigen-3 recognized by the monoclonal antibody (MAb) SSEA-3 was expressed in 60% of undifferentiated parental NT2D1 or NT2D1 neo cells and in only 20% of NT2D1 CRIPTO anti-sense transfectants, whereas it was down-regulated in all cell lines following RA treatment. A neuroectodermal antigen recognized by the A2B5 MAb, which was not expressed in parental NT2D1, in NT2D1 neo or in CRIPTO anti-sense NT2D1 cells, was induced by RA treatment in all cell lines. Taken together, our results show that inhibition of endogenous CRIPTO expression in human embryonal carcinoma cells interferes with both transformation and differentiation.

AB - CRIPTO is a member of the epidermal growth factor (FGF) gene family originally isolated from undifferentiated human NTERA2 clone D1 (NTZD1) multipotent embryonal carcinoma cells. Retinoic acid (RA) treatment of NT2D1 cells leads to a neuronal differentiation program and to concomitant loss of CRIPTO mRNA expression. To assess the role of CRIPTO in the control of NTZD1 cell growth or differentiation, these cells were treated with 3 anti-sense oligodeoxynucleotides complementary to the 5' end of the human CRIPTO mRNA. A dosedependent inhibition of monolayer and soft agar growth was observed with each of these CRIPTO anti-sense oligodeoxynucleotides but not with a control oligodeoxynucleotide of random sequence or with the 3 corresponding CRIPTO sense oligodeoxynucleotides. In addition, NTZD1 cells were transfected with a recombinant expression vector containing a 918-bp coding fragment of the human CRIPTO cDNA in the 3' to 5' orientation. NTZD1 CRIPT anti-sense transfectants exhibited a significantly reduced endogenous CRIPTO mRNA and protein, a 4- to 5-fold decrease in growth rate in monolayer and a 50-70% reduction in cloning efficiency in soft agar as compared with NT2D1 parental cells or with NT2D1 cells transfected with a plasmid containing the neomycin-resistance gene alone (NT2D1 neo cells). Finally, we examined the expression of immunophenotypic markers that are modulated during the differentiation of NT2D1 cells following RA treatment. The globoseries stage-specific embryonic antigen-3 recognized by the monoclonal antibody (MAb) SSEA-3 was expressed in 60% of undifferentiated parental NT2D1 or NT2D1 neo cells and in only 20% of NT2D1 CRIPTO anti-sense transfectants, whereas it was down-regulated in all cell lines following RA treatment. A neuroectodermal antigen recognized by the A2B5 MAb, which was not expressed in parental NT2D1, in NT2D1 neo or in CRIPTO anti-sense NT2D1 cells, was induced by RA treatment in all cell lines. Taken together, our results show that inhibition of endogenous CRIPTO expression in human embryonal carcinoma cells interferes with both transformation and differentiation.

UR - http://www.scopus.com/inward/record.url?scp=0029890271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029890271&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0215(19960516)66:4<538::AID-IJC19>3.0.CO;2-3

DO - 10.1002/(SICI)1097-0215(19960516)66:4<538::AID-IJC19>3.0.CO;2-3

M3 - Article

C2 - 8635871

AN - SCOPUS:0029890271

VL - 66

SP - 538

EP - 543

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 4

ER -